Zogenix (NASDAQ:ZGNX) has resubmitted its marketing application to the FDA seeking approval of FINTEPLA (fenfluramine) for the treatment of a severe form of childhood-onset epilepsy called Dravet syndrome.
In April it received a Refusal to File letter from the agency meaning that the application was not complete enough to review.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.